Virtual Library
Start Your Search
Jeronimo Rafael Rodriguez-Cid
Author of
-
+
P2.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 707)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.06-007 - Demographic Characteristics of Lung Cancer and Association with Wood Smoke in Mexican Population (ID 9638)
09:30 - 16:00 | Presenting Author(s): Jeronimo Rafael Rodriguez-Cid
- Abstract
Background:
Retrospective, longitudinal, unicentric and cohort study that analyzes the demographic characteristics of the Mexican population with lung cancer and its association with wood smoke exposure.
Method:
The study had 123 patients pathologically diagnosed with lung cancer between January 2013 to January 2014 at the National Institute of Respiratory Diseases. The primary endpoint was the histological type of lung cancer and the secondary the rate of exposure to wood smoke. Two cohorts were analyzed, the first with patients without exposure to wood smoke and the second with no exposure.
Result:
The sample was formed by 68 men (55.3%) and 55 women (44.7%). They were smokers in 47.2% of the patients, with an average of 12.7 packs/year. The 47.15% had exposure to smoke from wood, with an average of 77.5 hours/year. The 88.6% had non-small-cell lung cancer (69.9% adenocarcinoma, 11.4% squamous and 7.3% other types), and 11.4% small cell lung cancer. The EGFR mutation was positive in 21% of adenocarcinomas. Patients with diagnosis of adenocarcinoma had the highest exposure to wood smoke (p<0.003). The cohort for exposure to wood smoke was significant for the development of lung cancer was 61 hours/year (p <0.001).
Conclusion:
The histological type of lung cancer most prevalent was adenocarcinoma, present in women with high exposure of wood smoke. The cohort of 61 hours/year was determined as a risk factor, the latter is not a predictor of EGFR mutation.
-
+
P2.07 - Immunology and Immunotherapy (ID 708)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.07-061 - Nivolumab for Patients with Non-Small Cell Lung Carcinoma in Patients with Progression to One or More Lines of Chemotherapy in Mexican Population (ID 10092)
09:30 - 16:00 | Presenting Author(s): Jeronimo Rafael Rodriguez-Cid
- Abstract
Background:
: Nivolumab is a PD-1 inhibitor that has been approved as a treatment in adenocarcinoma and squamous cell lung cancer. This study examines the experience with nivolumab as a compassionate use in Mexican patients.
Method:
Descriptive, observational, retrospective and unicentric study that analyzed 38 patients diagnosed with stage III and IV lung cancer who progressed to one or more line of chemotherapy and received nivolumab from April 2016 to March 2017 at the National Institute of Respiratory Diseases. The primary endpoint was overall survival and secondary progression-free survival and response rate measured based on RECIST 1.1.
Result:
The sample was formed by 12 men (35.3%) and 22 women (64.7%), that had an initial ECOG of I in 23.5%, II in 58.5% and III in 17.6% and clinical stages was III 2.9% and IV 97.1%. They were smokers in 52.8% of the patients, with an average of 9.1 packs/year and 47.1% had exposure to smoke from wood, with an average of 62.1 hours/year. The 88.2% had adenocarcinoma, 5.9% squamous, from which 54.4% received nivolumab in second line and 45.6% in third line or more. The median progression-free survival was 8.1 months. The average overall survival, has not been able to achieve since 12 moths of treatment, the 51.4% of patients still alive. The response to the treatment by RECIST 1.1 was 38.2% for partial response (13 patients), stable disease in 41.2% (14 patients) and complete response 20.6% (7 patients).
Conclusion:
The use of nivolumab in patients with non-small cell lung carcinoma in advanced clinical stages (III and IV) progressing to a first line or more of chemotherapy demonstrated a better progression-free survival and overall survival in Mexican patients.
